Alzheimer's disease risk associated with changes in Epstein-Barr virus nuclear antigen 1-specific epitope targeting antibody levels.

[1]  Kaifei Xu,et al.  Neurotropic virus infection and neurodegenerative diseases: Potential roles of autophagy pathway , 2023, CNS neuroscience & therapeutics.

[2]  C. Whitehurst,et al.  Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients , 2023, Virus Research.

[3]  M. Nalls,et al.  Virus exposure and neurodegenerative disease risk across national biobanks , 2023, Neuron.

[4]  Rui Qiao,et al.  Integrated bioinformatics-based identification of diagnostic markers in Alzheimer disease , 2022, Frontiers in Aging Neuroscience.

[5]  D. Holtzman,et al.  Emerging roles of innate and adaptive immunity in Alzheimer's disease. , 2022, Immunity.

[6]  P. Lieberman,et al.  Cryo-EM Structure and Functional Studies of EBNA1 Binding to the Family of Repeats and Dyad Symmetry Elements of Epstein-Barr Virus oriP , 2022, Journal of virology.

[7]  Mark S. Anderson,et al.  Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM , 2022, Nature.

[8]  K. Lee,et al.  Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection , 2022, Frontiers in Immunology.

[9]  Di Wu,et al.  Regulation of the Late Onset alzheimer’s Disease Associated HLA-DQA1/DRB1 Expression , 2022, American journal of Alzheimer's disease and other dementias.

[10]  R. Pondé.  Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti‐HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure , 2021, Microbiology and immunology.

[11]  E. Chakravarty,et al.  Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus , 2021, Journal of translational autoimmunity.

[12]  S. Li,et al.  Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern , 2021, JCI insight.

[13]  E. Rogaev,et al.  Therapeutic B-cell depletion reverses progression of Alzheimer’s disease , 2021, Nature Communications.

[14]  Xu Yan,et al.  Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease , 2020, Frontiers in Neuroscience.

[15]  Wei Liu,et al.  Relationship between fibrinogen level and its regulatory gene with Alzheimer’s disease and vascular dementia , 2020, The Journal of international medical research.

[16]  Sonja W. Scholz,et al.  Human Herpesvirus 6 Detection in Alzheimer’s Disease Cases and Controls across Multiple Cohorts , 2020, Neuron.

[17]  M. McClain,et al.  Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. , 2020, Journal of autoimmunity.

[18]  H. Lung,et al.  Reactivation of Epstein–Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn2+-chelating function , 2019, Proceedings of the National Academy of Sciences.

[19]  Byeong-Chae Kim,et al.  High-throughput epitope profiling of antibodies in the plasma of Alzheimer’s disease patients using random peptide microarrays , 2019, Scientific Reports.

[20]  F. Kametani,et al.  Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease , 2018, Front. Neurosci..

[21]  C. Epperson,et al.  Considering sex and gender in Alzheimer disease and other dementias , 2016, Dialogues in clinical neuroscience.

[22]  Brandalyn C. Riedel,et al.  Age, APOE and sex: Triad of risk of Alzheimer’s disease , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  M. Hecker,et al.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients* , 2016, Molecular & Cellular Proteomics.

[24]  D. Gatherer,et al.  Modelling the structure of full-length Epstein–Barr virus nuclear antigen 1 , 2014, Virus Genes.

[25]  Chadwick M. Hales,et al.  Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer’s Disease , 2014, Journal of proteome research.

[26]  G. Silverman,et al.  Natural IgM: Beneficial Autoantibodies for the Control of Inflammatory and Autoimmune Disease , 2014, Journal of Clinical Immunology.

[27]  B. Sugden,et al.  Epstein-Barr viral productive amplification reprograms nuclear architecture, DNA replication, and histone deposition. , 2013, Cell host & microbe.

[28]  T. Elbert,et al.  Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients , 2013, PloS one.

[29]  D. Řípová,et al.  Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament , 2012, Journal of Neuroimmunology.

[30]  L. Frappier,et al.  Functions of the Epstein-Barr Virus EBNA1 Protein in Viral Reactivation and Lytic Infection , 2012, Journal of Virology.

[31]  B. Ford,et al.  Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns , 2009, Journal of Clinical Microbiology.

[32]  S. Aras,et al.  Zinc Coordination Is Required for and Regulates Transcription Activation by Epstein-Barr Nuclear Antigen 1 , 2009, PLoS pathogens.

[33]  J. Lünemann,et al.  Epstein-Barr virus and multiple sclerosis , 2007, Current neurology and neuroscience reports.

[34]  Albert Hofman,et al.  Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.

[35]  P. Hof,et al.  Humoral immunity in brain aging and Alzheimer's disease , 2005, Brain Research Reviews.

[36]  A. Kudoh,et al.  In Vivo Dynamics of EBNA1-oriP Interaction during Latent and Lytic Replication of Epstein-Barr Virus* , 2004, Journal of Biological Chemistry.

[37]  M. Gulley.  Molecular diagnosis of Epstein-Barr virus-related diseases. , 2001, The Journal of molecular diagnostics : JMD.

[38]  M. Rossor,et al.  Association between autoimmune thyroid disease and Familial Alzheimers disease , 1991, Clinical endocrinology.

[39]  P. Hartikainen,et al.  Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease. , 2017, The Journal of investigative dermatology.

[40]  V. Tsetlin,et al.  The presence and origin of autoantibodies against α4 and α7 nicotinic acetylcholine receptors in the human blood: possible relevance to Alzheimer's pathology. , 2011, Journal of Alzheimer's disease : JAD.

[41]  M. D'Andrea.  Add Alzheimer's disease to the list of autoimmune diseases. , 2005, Medical hypotheses.

[42]  Journal of Neuroinflammation BioMed Central Review Involvement of β-chemokines in the development of inflammatory demyelination , 2005 .